//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Simulpub number 6 at #ERA26 Obi beats tacrolimus in membranous nephropathy www.nejm.org/doi/full/10.... in NEJM No surprise after MENTOR
Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab ...
www.nejm.org
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy | NEJM
8d
Swapnil Hiremath 🍁🇨🇦